RETROMOX228.5 DRY SYRUP

Amoxycillin, a semisynthetic penicillin antibiotic, works by inhibiting bacterial cell wall synthesis, leading to the destruction of susceptible bacteria. However, some bacteria produce β-lactamase enzymes that can deactivate amoxycillin. Clavulanic Acid, a β-lactamase inhibitor, neutralizes these enzymes, protecting amoxycillin from inactivation. This synergistic combination enhances the effectiveness of the antibiotic and broadens its antimicrobial coverage, making RETROMOX 228.5 Dry Syrup a reliable choice for various pediatric bacterial infections.

RETROMOX 228.5 Dry Syrup is indicated for the treatment of upper and lower respiratory tract infections, otitis media, sinusitis, tonsillitis, pharyngitis, urinary tract infections, skin and soft tissue infections, and other bacterial infections in children. It provides quick relief from fever, throat pain, earache, and other infection symptoms, promoting faster recovery. The formulation is designed to be palatable and easy to administer, ensuring better acceptance and adherence among pediatric patients.

Manufactured under stringent quality control and safety standards, RETROMOX 228.5 Dry Syrup ensures consistent potency, high bioavailability, and effective antibacterial action. It is safe and well-tolerated in children when used under medical guidance. With its proven combination of Amoxycillin and Clavulanic Acid, RETROMOX 228.5 Dry Syrup delivers comprehensive infection management — ensuring faster recovery, minimal recurrence, and reliable protection for growing children.